Raju Mohan
Founder presso VENTYX BIOSCIENCES, INC.
Patrimonio netto: 9 M $ in data 31/03/2024
Profilo
Raju S.
Mohan is the founder.
He founded Zomagen Biosciences Ltd.
in 2018, Akarna Therapeutics Ltd.
in 2014, Ventyx Biosciences, Inc. in 2018, and Vimalan Biosciences, Inc. in 2017.
Dr. Mohan is also the founder of Escalier Biosciences BV.
Dr. Mohan's current job(s) include being a Director at Oppilan Pharma Ltd.
since 2015 and a Partner & Senior Advisor at New Science Ventures LLC since 2017.
Dr. Mohan's former job(s) include being the Vice President & Head-San Diego Site at Exelixis, Inc. from 2006 to 2011 and the Vice President-Chemistry at X-Ceptor Therapeutics, Inc. from 2004 to 2006.
Dr. Mohan's education history includes graduating from the Indian Institute of Technology Bombay and obtaining a doctorate degree from the University of Illinois At Urbana–Champaign.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
VENTYX BIOSCIENCES, INC.
2.66% | 02/04/2024 | 1 578 250 ( 2.66% ) | 9 M $ | 31/03/2024 |
Posizioni attive di Raju Mohan
| Società | Posizione | Inizio |
|---|---|---|
| VENTYX BIOSCIENCES, INC. | Founder | 01/11/2018 |
Oppilan Pharma Ltd.
 Oppilan Pharma Ltd. BiotechnologyHealth Technology Oppilan Pharma Ltd. operates as a biotechnology company. The company is headquartered in Cambridge, the United Kingdom. | Director/Board Member | 27/05/2015 |
Escalier Biosciences BV
 Escalier Biosciences BV BiotechnologyHealth Technology Escalier Biosciences BV develops biological products. The company is headquartered in Nijmegen, the Netherlands. | Founder | - |
New Science Ventures LLC
 New Science Ventures LLC Investment ManagersFinance New Science Ventures LLC (New Science Ventures) is a venture capital firm founded in 2004 by Somasundaram Subramaniam and Tom J A Lavin. The firm is headquartered in Greenwich, Connecticut with additional office in London. | Private Equity Investor | 01/01/2017 |
| Vimalan Biosciences, Inc. | Founder | 01/10/2017 |
Precedenti posizioni note di Raju Mohan
| Società | Posizione | Fine |
|---|---|---|
| EXELIXIS, INC. | Corporate Officer/Principal | 01/01/2011 |
X-Ceptor Therapeutics, Inc.
 X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Corporate Officer/Principal | 01/01/2006 |
| Zomagen Biosciences Ltd. | Founder | - |
Akarna Therapeutics Ltd.
 Akarna Therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Akarna Therapeutics Ltd. develops novel small molecule therapeutics. It offers non-bile acid FXR agonist, a therapeutic for the treatment of nonalcoholic steatohepatitis and fatty-liver diseases. The company was founded by Raju Mohan in 2014 and is headquartered in Cambridge, the United Kingdom. | Founder | - |
Formazione di Raju Mohan
| Indian Institute of Technology Bombay | Graduate Degree |
| University of Illinois At Urbana–Champaign | Doctorate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| EXELIXIS, INC. | Health Technology |
| Aziende private | 8 |
|---|---|
X-Ceptor Therapeutics, Inc.
X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Commercial Services |
New Science Ventures LLC
New Science Ventures LLC Investment ManagersFinance New Science Ventures LLC (New Science Ventures) is a venture capital firm founded in 2004 by Somasundaram Subramaniam and Tom J A Lavin. The firm is headquartered in Greenwich, Connecticut with additional office in London. | Finance |
Akarna Therapeutics Ltd.
Akarna Therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Akarna Therapeutics Ltd. develops novel small molecule therapeutics. It offers non-bile acid FXR agonist, a therapeutic for the treatment of nonalcoholic steatohepatitis and fatty-liver diseases. The company was founded by Raju Mohan in 2014 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Oppilan Pharma Ltd.
Oppilan Pharma Ltd. BiotechnologyHealth Technology Oppilan Pharma Ltd. operates as a biotechnology company. The company is headquartered in Cambridge, the United Kingdom. | Health Technology |
Escalier Biosciences BV
Escalier Biosciences BV BiotechnologyHealth Technology Escalier Biosciences BV develops biological products. The company is headquartered in Nijmegen, the Netherlands. | Health Technology |
| Ventyx Biosciences, Inc. | |
| Zomagen Biosciences Ltd. | |
| Vimalan Biosciences, Inc. |
- Borsa valori
- Insiders
- Raju Mohan
